Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women

Christensen, Palle Mark, Brixen, Kim, Gyrd-Hansen, Dorte and Kristiansen, Ivar Sonbo (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic and Clinical Pharmacology and Toxicology, 96 5: 387-396. doi:10.1111/j.1742-7843.2005.pto_08.x

Author Christensen, Palle Mark
Brixen, Kim
Gyrd-Hansen, Dorte
Kristiansen, Ivar Sonbo
Title Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women
Journal name Basic and Clinical Pharmacology and Toxicology   Check publisher's open access policy
ISSN 1742-7835
Publication date 2005-05-01
Sub-type Article (original research)
DOI 10.1111/j.1742-7843.2005.pto_08.x
Volume 96
Issue 5
Start page 387
End page 396
Total pages 10
Place of publication Oxford, United Kingdom
Publisher Wiley-Blackwell Publishing
Language eng
Abstract Pharmacological interventions for osteoporosis may reduce morbidity and mortality, but they incur additional health care costs. The aim was to quantify the additional costs and health benefits of prescribing alendronate 10 mg and calcium/vitamin D daily for 71-year-old women with a fracture risk twice that of the population average in stead of calcium/vitamin D alone. A state transition model based primarily on Scandinavian data was developed. Women were followed from age of 71 years until 100. Alendronate was assumed to reduce the fracture risk by 50%. Health benefits from the interventions were expressed in terms of life years, quality adjusted life years, and fractures avoided. Societal costs were estimated using literature estimates and Danish tariffs. All costs were measured in 2002 Danish Kroner (DKK). Future costs and benefits were discounted at 5% per year. The incremental cost per QALY gained was DKK125,000 while the cost per life year gained was DKK 374,000. The use of alendronate was cost-saving when 1) the treatment was extended to five years, 2) the risk of fracture was four times the population average, 3) the effect of alendronate was assumed to persist for three years after discontinuation of treatment, 4) a greater proportion had severe sequelae after a hip fracture, or 5) the start of therapy was delayed until age of 77 years. In conclusion, the use of alendronate compares well with other well established therapies in terms of cost-effectiveness in older women with high risk of fracture.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: ERA 2012 Admin Only
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 17 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 18 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 20 Oct 2011, 20:11:00 EST by System User on behalf of Medicine - Royal Brisbane and Women's Hospital